You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 28, 2024

CLINICAL TRIALS PROFILE FOR TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Tipiracil Hydrochloride; Trifluridine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01955837 ↗ Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia Completed Taiho Pharmaceutical Co., Ltd. Phase 3 2013-09-01 To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies.
NCT02654639 ↗ Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer Terminated Georgetown University Phase 2 2016-02-01 Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC
NCT03278106 ↗ TAS-102 in Treating Advanced Biliary Tract Cancers Active, not recruiting National Cancer Institute (NCI) Phase 2 2017-10-20 This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT03278106 ↗ TAS-102 in Treating Advanced Biliary Tract Cancers Active, not recruiting Mayo Clinic Phase 2 2017-10-20 This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT03297710 ↗ TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery Active, not recruiting National Cancer Institute (NCI) Phase 1 2017-12-11 This phase I trial studies the side effects and best dose of trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) when given together with radiation therapy in treating patients with rectal cancer that has come back, spread to other places in the body, or cannot be removed by surgery. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving TAS-102 with radiation therapy may kill more tumor cells.
NCT03297710 ↗ TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery Active, not recruiting Mayo Clinic Phase 1 2017-12-11 This phase I trial studies the side effects and best dose of trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) when given together with radiation therapy in treating patients with rectal cancer that has come back, spread to other places in the body, or cannot be removed by surgery. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving TAS-102 with radiation therapy may kill more tumor cells.
NCT03306394 ↗ A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic). Completed ADIR, a Servier Group company Phase 3 2016-10-18 The purpose of this study is to collect additional safety and efficacy data during treatment with trifluridine / tipiracil in patients with a pretreated metastatic colorectal cancer (mCRC). Eligible patients may receive an early access to trifluridine / tipiracil through this clinical study until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor's prescription or can be accessed from another source or Sponsor decision.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tipiracil Hydrochloride; Trifluridine

Condition Name

Condition Name for Tipiracil Hydrochloride; Trifluridine
Intervention Trials
Metastatic Colorectal Cancer 11
Colorectal Cancer 7
Stage IV Colorectal Cancer AJCC v8 6
Stage IVB Colorectal Cancer AJCC v8 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tipiracil Hydrochloride; Trifluridine
Intervention Trials
Colorectal Neoplasms 37
Adenocarcinoma 16
Colonic Neoplasms 8
Carcinoma 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tipiracil Hydrochloride; Trifluridine

Trials by Country

Trials by Country for Tipiracil Hydrochloride; Trifluridine
Location Trials
United States 111
Italy 27
China 23
Japan 18
Australia 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tipiracil Hydrochloride; Trifluridine
Location Trials
California 10
Arizona 8
Florida 8
Minnesota 8
Texas 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tipiracil Hydrochloride; Trifluridine

Clinical Trial Phase

Clinical Trial Phase for Tipiracil Hydrochloride; Trifluridine
Clinical Trial Phase Trials
Phase 3 11
Phase 2 30
Phase 1/Phase 2 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tipiracil Hydrochloride; Trifluridine
Clinical Trial Phase Trials
Recruiting 26
Not yet recruiting 13
Active, not recruiting 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tipiracil Hydrochloride; Trifluridine

Sponsor Name

Sponsor Name for Tipiracil Hydrochloride; Trifluridine
Sponsor Trials
National Cancer Institute (NCI) 14
Servier 4
Mayo Clinic 4
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tipiracil Hydrochloride; Trifluridine
Sponsor Trials
Other 52
Industry 30
NIH 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.